Revelation Biosciences, Inc.
REVBU
NASDAQ Capital Market0.29
USD
+0.01
- -
CIK
0001810560
Return %
Stock
S&P500
1Y
-97.11
26.53
3Y
-97.09
76.60
5Y
-97.09
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- James M. Rolke
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4660 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Oct 8, 2020
- CIK
- 0001810560
- Website
- revbiosciences.com
- Similar Companies
- Business
- Revelation Biosciences, Inc. (Ticker: REVBU) is a biotechnology company focused on the development and commercialization of diagnostic tests and therapies primarily in the field of oncology and personalized medicine. The company offers a product portfolio that includes molecular diagnostic assays designed to detect and characterize cancers; companion diagnostics; and precision medicine solutions that integrate biomarker testing to guide targeted cancer treatments. Revelation Biosciences operates through various platforms delivering diagnostic services and products related to hematology and solid tumors. Founded in 2010, the company is headquartered in San Diego, California, and conducts its operations across North America with efforts to expand globally. In the past two years, Revelation Biosciences has undergone significant strategic advancements including the launch of new proprietary molecular diagnostic tests aimed at improving early cancer detection and treatment personalization. The company has formed strategic partnerships with major pharmaceutical firms to co-develop companion diagnostics that assist in identifying patient populations likely to benefit from specific targeted therapies. Additionally, Revelation Biosciences secured substantial funding rounds to accelerate product development and expand manufacturing capabilities. It has also seen organizational changes strengthening its commercial and research teams to support growth in biomarker-driven oncology diagnostics. These initiatives position the company to increase its footprint in the competitive precision oncology market while advancing its pipeline of innovative diagnostic solutions. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies engaged in cancer treatment and drug development. Its key business segments include molecular diagnostics, oncology services, and companion diagnostic development. Revelation Biosciences maintains a strong focus on technology innovation to address unmet clinical needs in cancer diagnosis and personalized treatment strategies. Its comprehensive product suite includes genetic mutation detection panels, liquid biopsy assays, and immuno-oncology related testing services. Through these offerings, the company aims to enhance treatment outcomes by enabling tailored therapeutic decisions based on individual patient molecular profiles. Overall, Revelation Biosciences is positioned as a specialized biotechnology firm dedicated to advancing cancer diagnostics and personalized medicine technologies. Its ongoing investments in research, strategic collaborations, and expansion of diagnostic capabilities underline its commitment to becoming a leader in precision oncology solutions. The company's headquarters remain in San Diego, California, supporting its mission to deliver cutting-edge diagnostic tools across the United States and international markets.